

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib
Close
Treatment Agent: Zanubrutinib
Synopsis: You are being asked to take part in this study because you have been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
The purpose of this study is to study the safety and efficacy of the study drug zanubrutinib (also known as BGB-3111) in Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) patients who discontinued prior ibrutinib treatment due to toxicities.
Zanubrutinib is an experimental drug. This means that it has not been approved for use by the regulatory agencies in any country, but it can be used in research studies such as this one. As of September 2018, zanubrutinib has been given to approximately 1200 participants who are taking or have taken part in research studies with zanubrutinib as a single drug or in combination with another anticancer drug.
Zanubrutinib blocks a protein called Bruton Tyrosine Kinase (BTK). BTK helps CLL/SLL cells live and grow. By blocking BTK, zanubrutinib is capable of stopping or slowing down the growth and activity of CLL/SLL cells, which can lead to improvement in the symptoms associated with CLL/SLL. However, not all patients will improve to the same degree, and some patients might not improve at all.
Close
Close
Close
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Close
Treatment Agent: N/A
Synopsis: The purpose of this study is to gather data on patients like you, who have been diagnosed with classical Hodgkin Lymphoma (cHL). The study aims to collect information on how treatment for cHL is rendered, as well as assess the outcome of those treatment options.
Close
Close
Other protocol defined inclusion/exclusion criteria could apply
Close
Interested in a
Clinical Trial?